Phase I Safety and Clinical Activity Study of Thymoquinone in Patients with Advanced Refractory Malignant Disease.

Authors

Ali M. Al-Amri, MD1,*, Abdullah O. Bamosa MBBS, PHD2
1Department of Internal Medicine/Oncology, College of Medicine, King Faisal University, King Fahd Hospital of the University, Al-Khobar, Eastern Province, Kingdom of Saudi Arabia.
2Department of Physiology, College of Medicine, King Faisal University, Dammam, Saudi Arabia.
*Corresponding Author: Department of Internal Medicine and Oncology, King Fahd Hospital of the University, Kingdom of Saudi Arabia, Telephone: +966(3) 8580-107, Fax +966(3) 8966-741, [email protected]. Email: [email protected]

Shiraz E-Medical Journal:Vol. 10, issue 3; 107-11
Published online:Jul 01, 2009
Article type:Research Article
Received:Jan 19, 2009
Accepted:Apr 20, 2009
How to Cite:Al-Amri, MD AM, MBBS, PHD AOB. Phase I Safety and Clinical Activity Study of Thymoquinone in Patients with Advanced Refractory Malignant Disease.. Shiraz E-Med J. 2009;10(3):. doi:

Abstract

Purpose:

This phase I study was conducted to determine the general toxicities of thymoquinone in humans, as well as any anti-cancer effects that the drug may have in patients with advanced cancer for which there were no standard curative or palliative measures.

Patients and methods:

Adult patients with solid tumors or hematological malignancies who had failed or relapsed from standard therapy were included in this study. Patients who were at least 18 years of age with an Eastern cooperative oncology group performance status (ECOG) of ? 2 received thymoquinone orally at a starting dose level of 3, 7, or 10mg/kg/day. Dose escalation proceeded according to a modified Fibonacci design.

Results:

All 21 patients received at least one week of treatment, with a median of 3.71 weeks (range 1 week to 20 weeks). No side effects were reported and the maximum tolerated dose (MDT) was not identified. No anti-cancer effects were observed.

Conclusion:

On the basis of this study, thymoquinone was well tolerated at a dose ranging from 75mg/day to 2600mg/day. Neither toxicities nor therapeutic responses were reported.

Highlights

Full Text

Full text is available in PDF

Copyright

© 2009, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

1
Sep
2023

The effect of Thymoquinone on Peripheral Blood Mononuclear Cells (PBMCs) viability of patients with B-Chronic Lymphocytic Leukemia

Maral Hemati,
Maryam Abdollahi,
Mehrnoosh Pashaei,
Farahnaz Ghahremanfard,
Parviz Kokhaei

Hemati M, Abdollahi M, Pashaei M, Ghahremanfard F, Kokhaei P. The effect of Thymoquinone on Peripheral Blood Mononuclear Cells (PBMCs) viability of patients with B-Chronic Lymphocytic Leukemia. koomesh. 2023;25(2):e152812. doi:

20
Nov
2010

In Vitro Challenge using Thymoquinone on Hepatocellular Carcinoma (HepG2) Cell Line

Sohair A. Hassan,
Wafaa A. Ahmed,
Fayek M. Galeb,
Maha A. El-Taweel,
Farid A. Abu-Bedair

Hassan SA, Ahmed WA, Galeb FM, El-Taweel MA, Abu-Bedair FA. In Vitro Challenge using Thymoquinone on Hepatocellular Carcinoma (HepG2) Cell Line. Iran J Pharm Res. 2022;7(4):e128603. doi: https://doi.org/10.22037/ijpr.2010.777

26
Dec
2023
Designing and Synthesis of an Anti-Candida parapsilosis Thymoquinone Lipid Formulation

Designing and Synthesis of an Anti-Candida parapsilosis Thymoquinone Lipid Formulation

Ardalan Ghiaee Shamloo,
Mohammad Hossein Yadegari,
Shahla Roudbar Mohammadi,
Mahmoodreza Jaafari,
Hossein Zarrinfar

Ghiaee Shamloo A, Yadegari MH, Roudbar Mohammadi S, Jaafari M, Zarrinfar H. Designing and Synthesis of an Anti-Candida parapsilosis Thymoquinone Lipid Formulation. Jundishapur J Microbiol. 2023;16(10):e141934. doi: https://doi.org/10.5812/jjm-141934

30
Jun
2019

In vitro Cytobiological Effects of Phytochemicals from Artemisia turanica

Mahboubeh Taherkhani

Taherkhani M. In vitro Cytobiological Effects of Phytochemicals from Artemisia turanica. J Rep Pharm Sci. 2019;8(1):e147486. doi: https://doi.org/10.4103/jrptps.jrptps_37_18

30
Apr
2015

The Comparison of Anticancer Activity of Thymoquinone and Nanothymoquinone on Human Breast Adenocarcinoma

Hossein Dehghani,
Mehrdad Hashemi,
Maliheh Entezari,
Afshin Mohsenifar

Dehghani H, Hashemi M, Entezari M, Mohsenifar A. The Comparison of Anticancer Activity of Thymoquinone and Nanothymoquinone on Human Breast Adenocarcinoma. Iran J Pharm Res. 2015;14(2):e125355. doi: https://doi.org/10.22037/ijpr.2015.1648

More by these authors

Ali M. Al-Amri, MDPubMedScholar
Abdullah O. Bamosa MBBS, PHDPubMedScholar
Share
Cited by
Metrics